The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000630314
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
5/03/2026
Date registered
Help: Date registered
22/05/2026
Date last updated
Help: Date last updated
22/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
22/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A Single-Case Experimental Study to Assess Temporal Change During the StressModex Intervention for People with Acute/ Sub-Acute Whiplash-Associated Disorders.
Scientific title
A Single-Case Experimental Study to Assess Temporal Change During the StressModex Intervention for People with Acute/ Sub-Acute Whiplash-Associated Disorders.
Additional trial identifiers [1] 316024 0
Nil Known
Universal Trial Number (UTN)
U1111-1331-7472
Trial acronym
StressModex SCED
Related trial records

Health condition
Health condition(s) studied:
Acute Whiplash Associated Disorders (WAD) 339873 0
Sub-acute Whiplash Associated Disorders (WAD) 341097 0
Condition category
Condition code
Musculoskeletal 336103 336103 0 0
Other muscular and skeletal disorders
Injuries and Accidents 336104 336104 0 0
Other injuries and accidents
Physical Medicine / Rehabilitation 336175 336175 0 0
Physiotherapy

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Name: StressModex
• Description: Stress Modex is a structured, six-week, physiotherapist-delivered program integrating Stress Inoculation Training (SIT) with guideline-recommended physiotherapy exercise. The intervention combines education, skills training, and supervised exercise to support participants in recognising and managing stress and pain following acute or sub-acute whiplash-associated disorders.

• Materials: Community physiotherapists receive in-person training from a member of the research team in the Stress Modex protocol and its delivery prior to treating participants.

• Procedures: Participants attend one individual session per week for six weeks. Each session lasts approximately 60 minutes and introduces a new module of the Stress Modex intervention. Week 1 focuses on relaxed abdominal breathing. Week 2 introduces body scans, a mindfulness-based practice in which individuals systematically direct attention to different body parts, noticing sensations without judgment. Week 3 focuses on problem-solving techniques. Week 4 focuses on developing and practising adaptive coping self-statements. Week 5 emphasises practising SIT and coping skills in real-world stressful situations. Week 6 consolidates coping skills and focuses on maintaining gains over time.
In all sessions, physiotherapists also instruct participants in guideline-recommended physiotherapy exercise, deemed appropriate based on the physiotherapist’s physical assessment of the participant. Physiotherapy assessment of each patient underpins the exercise prescription and progression. The physiotherapist will tailor the management program to the individual patient’s presentation and functional goals. Guideline-recommended exercises for WAD include neck-specific range of motion and strengthening exercises, and sensorimotor control exercises of the head and neck. Advice and prescription of functional activities and general aerobic and strengthening exercises can be included based on the patient’s prior activity levels and functional goals. Some patients may need to commence exercises at a low intensity, but others may commence at a higher intensity.
Participants are encouraged to practise components of the intervention (e.g. relaxation, problem-solving, coping self-statements, and exercise) at least once per week at home between sessions to reinforce skills learned.

• Who will deliver the intervention: community physiotherapists who have undergone training by the research team in the Stress Modex protocol will deliver the intervention. The StressModex protocol has been created by the research team.

• Mode of delivery: The intervention is delivered individually, face-to-face. Participants are also encouraged to practise components of the intervention at home between sessions to reinforce skills learned.

• Number of times and duration: Participants attend one session per week for six weeks, with each session lasting approximately 60 minutes. Participants are encouraged to practise the techniques introduced in each module at least once per week at home to consolidate learning.

• Location: Participants will receive their intervention session in the physiotherapists clinic and then practice the skills learnt from a location of their choosing (e.g., at home).

• Personalisation: The physiotherapy exercise component is tailored according to the physiotherapist’s physical assessment of each participant. The psychological skills components follow the structured sequence described above but may be discussed using examples relevant to the participant’s own stressors.

•Adherence: Physiotherapists’ completion of all StressModex components within each session will be monitored and participant attendance at sessions will be recorded. Participants’ self-reported home practice will also be documented to provide an indication of adherence.
Intervention code [1] 332635 0
Rehabilitation
Intervention code [2] 332636 0
Behaviour
Intervention code [3] 333471 0
Treatment: Other
Description of the comparator or control
Participants act as their own control.
During the baseline phase, participants continue with their normal routine. The baseline period is either 7, 12 or 17 days depending on which baseline period they are randomly assigned to.
Participants complete daily assessments of pain and stress for the baseline period.
Control group
Active

Outcomes
Primary outcome [1] 343640 0
Daily pain interference
Timepoint [1] 343640 0
Daily for 50-60 consecutive days (spanning baseline and treatment phases).
Primary outcome [2] 343641 0
Daily Stress
Timepoint [2] 343641 0
Daily for 50-60 consecutive days (spanning baseline and treatment phases).
Secondary outcome [1] 455008 0
Daily pain intensity
Timepoint [1] 455008 0
Daily 50-60 consecutive days (spanning baseline and treatment phases).
Secondary outcome [2] 455009 0
Daily pain bothersomeness
Timepoint [2] 455009 0
Daily 50-60 consecutive days (spanning baseline and treatment phases).
Secondary outcome [3] 455010 0
Pain-related beliefs
Timepoint [3] 455010 0
At the end of each phase, and then six months after the completion of the intervention.
Secondary outcome [4] 455011 0
Stress
Timepoint [4] 455011 0
At the end of the baseline phase, end of the treatment phase and then six months after treatment.
Secondary outcome [5] 455012 0
Neck pain-related disability
Timepoint [5] 455012 0
At the end of the baseline phase, end of the treatment phase and then six months after treatment.
Secondary outcome [6] 455013 0
Post-traumatic stress symptoms
Timepoint [6] 455013 0
At the end of the baseline phase, end of the treatment phase and then six months after treatment.
Secondary outcome [7] 455014 0
Pain self-efficacy
Timepoint [7] 455014 0
At the end of the baseline phase, end of the treatment phase and then six months after treatment.
Secondary outcome [8] 455015 0
Perceived recovery
Timepoint [8] 455015 0
At the end of the baseline phase, end of the treatment phase and then six months after treatment.
Secondary outcome [9] 455016 0
Pain coping
Timepoint [9] 455016 0
At the end of the baseline phase, end of the treatment phase and then six months after treatment.
Secondary outcome [10] 455017 0
Heart rate variability (HRV)
Timepoint [10] 455017 0
Daily 50-60 consecutive days (spanning baseline and treatment phases).
Secondary outcome [11] 455018 0
Athlete's evaluation of their satisfaction with wearing heart rate monitor every day during the study period
Timepoint [11] 455018 0
At the end of the treatment phase.
Secondary outcome [12] 455019 0
Feasibility of heart rate monitor
Timepoint [12] 455019 0
Daily 50-60 consecutive days (spanning baseline and treatment phases).
Secondary outcome [13] 459061 0
Perceived pain controllability
Timepoint [13] 459061 0
At the end of each phase, and then six months after the completion of the intervention.
Secondary outcome [14] 459062 0
Behavioural and emotional responses to pain.
Timepoint [14] 459062 0
At the end of each phase, and then six months after the completion of the intervention.

Eligibility
Key inclusion criteria
(1) Whiplash associated disorder (WAD) grade two, less than 3 months post-injury,
(2) medium to high risk of non-recovery, as determined by the WhipPredict prognostic tool.
(3) not actively receiving psychological or medical treatment for WAD at the time of enrolment (excluding medications),
(4) aged over 18 years and proficient written and spoken English,
(5) access to the internet on a computer or smartphone,
(6) ability and willingness to physically attend the physiotherapy clinic during the six week intervention period.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
(1) known or suspected serious spinal pathology (e.g., metastatic disease of the spine),
(2) fracture or injury in other body areas as a result of the traffic accident,
(3) cervical spinal surgery in the past 12 months,
(4) medical or dermatological condition that prevents the safe and comfortable wear of a wrist-based heart rate monitor (e.g., severe skin sensitivity, open wounds, or musculoskeletal impairments affecting the wrist),
(5) meeting the criteria for probable acute stress disorder diagnosis on the Acute Stress Disorder Scale (ASDS)
(6) active malignancy (e.g., cancer not in remission), terminal illnesses, serious medical conditions that could interfere with trial participation or limit potential treatment benefits (e.g., lupus, self-report diagnosis of primary psychotic disorder, major thought disorder, or other unstable/severe psychiatric or behavioural conditions).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomised by software, stratified by baseline length, such that in each cohort one participant is randomly allocated to each of the three baseline lengths (7 days, 12 days, or 17 days)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
A SCED will be implemented, incorporating randomisation and systematic replication across participants. Specifically, a sequentially replicated, randomised AB phase design will serve as the primary design, with random assignment of intervention start points (7 days, 12 days, or 17 days after study commencement), thereby determining the length of the baseline phase (A).
Following baseline, participants enter the intervention (B) phase. This study adopts an embedded design structure, in which the primary AB phase design contains a secondary within-phase structure corresponding to the sequential delivery of intervention components.
Within phase B, the treatment is delivered in six consecutive weekly sessions based on the StressModex protoco. These sessions are conceptualised as embedded intervention components within the broader B phase, rather than as independent experimental phases. The components are as follows: (1) introduction to stress inoculation training (SIT), theoretical models of stress and pain, and abdominal breathing; (2) body scan exercises; (3) problem-solving for stressful situations; (4) positive coping statements; (5) application of stress inoculation skills in real-world contexts; and (6) coping skills maintenance. Thus, although the design is formally an AB phase design, it incorporates within-phase structuring of the intervention, allowing for exploratory examination of changes associated with the progressive introduction of treatment components while maintaining the primary experimental contrast between phase A and B.
The total study duration will be 50, 55, or 60 days depending on baseline length allocation.
Daily surveys of self-report measures will be completed across phases A tand B Qualitative semi-structured interviews will be conducted at the end of phase A, every two weeks during Phase B, and then six months after the completion of phase B, totalling 5 interviews. Wrist-based heart rate monitors will be worn daily during phases A and B to collect continuous heart rate data. Extended surveys with self-report measures will be conducted at the end of phase A, end of phase B and then six months after the end of phase B.
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Sample size: SCED design standards require at least three attempts to demonstrate an intervention effect at three different time points. Accordingly, a minimum of N=9 (three cohorts of three) participants with full, eligible data will be required to meet design standards. Participants who withdraw, are withdrawn, or are non-compliant will not be replaced due to the nature of the SCED design. To account for this, N = 12 participants will be recruited and tested in four cohorts of three.

Statistics:
• Primary Aim and Exploratory Aim 1: Structural visual analyses will follow SCED reporting guidelines. For each participant, time-series plots will be visually inspected, supplemented by statistical assessment of variability, trend, level, and overlap.
• Secondary Aim 1: Cross-lag correlation analyses, adjusted for autocorrelation, will be conducted using Simulation Modelling Analysis (SMA)..
• Secondary Aim 2: Qualitative interviews will be analysed thematically by two independent researchers using NVivo (Version 15). Discrepancies will be resolved through discussion with a third researcher. Themes will be compared across all time points.
• Exploratory Aim 2: One-way repeated-measures ANOVAs will be conducted across pre-treatment, post-treatment and follow-up. Greenhouse–Geisser corrections will be applied where sphericity is violated. Significant main effects will be followed by Bonferroni-adjusted pairwise comparisons.
• Exploratory Aim 3: Feasibility of wrist-based HRV monitoring will be evaluated through compliance and data-availability indices. For each participant, the percentage of days worn and the percentage of valid data across the 25-day period will be calculated. Thresholds = 80% for both metrics will indicate good feasibility. Participant ratings of simplicity, comfort, and perceived effectiveness (QUEST) will be summarised, and qualitative feedback will be analysed using thematic analysis.
Exploratory Aim 4: Physiological stress responses, indexed by HRV, will be examined for changes consistent with improved autonomic regulation (decreased SNS and increased PNS activity). Heart rate data will be processed in Kubios HRV Scientific (Version 4.1.0). For each valid segment, PNS and SNS indices will be calculated. Structural visual analyses will then be applied to these indices.


Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD

Funding & Sponsors
Funding source category [1] 320627 0
Government body
Name [1] 320627 0
National Health and Medical Research Council (NHMRC) Investigator Grant
Country [1] 320627 0
Australia
Primary sponsor type
University
Name
The University of Queensland
Address
Country
Australia
Secondary sponsor category [1] 323249 0
None
Name [1] 323249 0
Address [1] 323249 0
Country [1] 323249 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319168 0
The University of Queensland Human Research Ethics Committee A
Ethics committee address [1] 319168 0
Ethics committee country [1] 319168 0
Australia
Date submitted for ethics approval [1] 319168 0
07/10/2025
Approval date [1] 319168 0
12/01/2026
Ethics approval number [1] 319168 0
2025/HE001963

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 146474 0
Prof Michele Sterling
Address 146474 0
RECOVER Injury Research Centre The University of Queensland Level 7, Surgical Treatment and Rehabilitation Service, 296 Herston Road, HERSTON, QLD, 4029
Country 146474 0
Australia
Phone 146474 0
+61 7 3346 4793
Fax 146474 0
Email 146474 0
Contact person for public queries
Name 146475 0
Nicole Rickerby
Address 146475 0
RECOVER Injury Research Centre The University of Queensland Level 7, Surgical Treatment and Rehabilitation Service, 296 Herston Road, HERSTON, QLD, 4029
Country 146475 0
Australia
Phone 146475 0
+61401813973
Fax 146475 0
Email 146475 0
Contact person for scientific queries
Name 146476 0
Michele Sterling
Address 146476 0
RECOVER Injury Research Centre The University of Queensland Level 7, Surgical Treatment and Rehabilitation Service, 296 Herston Road, HERSTON, QLD, 4029
Country 146476 0
Australia
Phone 146476 0
+61 7 3346 4793
Fax 146476 0
Email 146476 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.